Attached files
| file | filename |
|---|---|
| 8-K - 8-K - NOVELION THERAPEUTICS INC. | novelion8-kapril112017.htm |
Exhibit 16.1
April 12, 2017
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read the statements made by Novelion in Item 4.01 of Novelion Therapeutics Inc.’s Current Report on Form 8-K dated April 11, 2017, and we agree with the statements concerning our Firm in such Form 8-K.
Yours truly,
/s/ DELOITTE LLP
Chartered Professional Accountants
Vancouver, Canada
Member of Deloitte Touche Tohmatsu Limited